Cue Health Inc. - HLTH STOCK NEWS

Cue Health (Nasdaq: HLTH) announced a collaboration with actress Gal Gadot to feature its new health smart device in a Super Bowl® commercial airing on February 13, 2022. The ad aims to position Cue as an essential tool for managing health at home. Cue offers the most accurate at-home COVID-19 test, providing results in 20 minutes via the Cue Health App. To enhance accessibility, the company has reduced prices for Cue+ memberships and COVID-19 tests. Cue Health is expanding its diagnostic offerings, focusing on personalized healthcare solutions.

On February 7, 2022, Cue Health (Nasdaq: HLTH) announced its partnership with Johns Hopkins Medicine (JHM) to provide Cue Health Monitoring Systems and Cue COVID-19 tests. The portable systems will be utilized by JHM's healthcare professionals to enhance employee health management. The Cue COVID-19 test, utilizing molecular nucleic acid amplification technology, delivers lab-quality results to mobile devices within 20 minutes and detects all known COVID-19 variants. Cue also supplies tests to various organizations, including Google and the NBA.

Cue Health (Nasdaq: HLTH) will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022 at 12:30 p.m. ET. The webcast is exclusive for conference attendees. Founded in 2010 and based in San Diego, Cue Health focuses on accessible health information, enabling real-time diagnostics for individuals and healthcare providers. They gained recognition for their pioneering COVID-19 test, the first FDA-authorized at-home molecular diagnostic test. Cue Health holds multiple international regulatory approvals.

Cue Health Inc. (NASDAQ: HLTH) announced preliminary unaudited revenue for Q4 and full year 2021. Q4 revenue was between $188 million and $193 million, up from $13 million in Q4 2020. Full year revenue reached $613 million to $618 million, compared to $23 million in 2020. The company reported cash equivalents of $412 million as of December 31, 2021. Significant partnerships were established, including collaborations with Cardinal Health and McKesson, and Cue expanded diagnostics offerings.

Cue Health (Nasdaq: HLTH) announced it will develop an Omicron-Genotyping COVID-19 test, partnering with the U.S. Department of Health and Human Services' BARDA. This test will enhance existing COVID-19 detection capabilities and is aimed at professional point-of-care settings. The funding from BARDA will expedite development and regulatory approval for a single-plex assay specifically targeting the Omicron variant. Cue's technology ensures accurate results in 20 minutes and has been recognized for its lab-quality diagnostics, benefitting patients and public health.

Cue Health (NASDAQ: HLTH), a healthcare technology firm, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference scheduled for January 11, 2022, at 5:15 p.m. Eastern Time. This presentation will be accessible via a live audio webcast on their website for 30 days post-event. Cue Health focuses on providing lab-quality diagnostics and real-time health information, revolutionizing home health management.

Cue Health (Nasdaq: HLTH) announces its first partnership with Air Canada to provide U.S. passengers access to its accurate molecular COVID-19 self-test. The test meets Canada’s entry requirements and can be purchased along with a portable Cue Cartridge Reader, delivering results in about 20 minutes. This partnership aims to enhance travel convenience and safety for Air Canada's U.S. customers, who can enjoy bilingual services expected in early 2022. Cue’s tests are already widely used in various critical settings and detect COVID-19 variants, including Omicron.

Cue Health Inc. (Nasdaq: HLTH) has appointed Nitin Duggal as its first Chief Marketing Officer, effective immediately. With over 15 years in technology organizations, Duggal will lead Cue's marketing strategies aimed at enhancing brand and product visibility. He previously held senior roles at Abbott Diabetes Care, promoting innovative health solutions. Co-founder and CEO Ayub Khattak praised Duggal's expertise in product marketing and expected contributions toward Cue's growth in the healthcare sector.

On December 1, 2021, Cue Health (Nasdaq: HLTH) announced it received Pandemic Special Access Route authorization from Singapore's Health Sciences Authority for its Cue COVID-19 Test, the first digital molecular diagnostic product authorized for home use in the country. This allows Cue to support public sector testing in Singapore through its partnership with Omnicell Pte Ltd. Cue plans to explore public and private partnerships to maximize the use of its diagnostic solutions. Additionally, Cue recently launched a direct-to-consumer health platform in the United States, offering a comprehensive health management solution.